Marksans Pharma said that the UK MHRA has granted market authorisation to the company's wholly owned subsidiary Relonchem for Fluoxetine 20mg/5ml oral solution.
The drug maker said that the therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK.
Mumbai-based Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets.
The drug maker consolidated net profit rose 29.9% to Rs 60.12 crore on a 25.3% increase in revenue from operations to Rs 452.56 crore in Q2 FY23 over Q2 FY22.
The scrip fell 1.41% to currently trade at Rs 66.20 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Great minds don’t just skim the surface, they uncover the full story.
You’ve hit your limit of {{free_limit}} free articles this month, subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
and get complimentary access to
Smart Quarterly
₹900
3 Months
₹300/Months/month
Smart Essential
₹2700
1 Year
₹225/Months/month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Unlimited access to all articles
30+ premium stories daily, handpicked by our editor
Complimentary Access to The New York Times
News, Games, Cooking, Audio
Wirecutter & The Athletic
Complimentary Access to Our e-Paper
Digital replica of our daily newspaper
Read, save, share any article
Curated Newsletters on Diverse Topics
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Smart Investment Tips
In-depth stock analysis & insights
The Smart Investor for wealth growth tips
Access to Extensive Historical Archives
Repository of articles and publications dating back to 1997
Ad-free Reading Experience
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Repository of articles and publications dating back to 1997